Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases

Journal of Lipid Research

Volumn 53, Issue 1, 2012, Pages 77-86

  Yang, Shao H ^a   Chang, Sandy Y ^a   Tu, Yiping ^a   Lawson, Gregory W ^a   Bergo, Martin O ^c   Fong, Loren G ^a   Young, Stephen G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Actin stress fibers; Hepatic steatosis; Hyperbilirubinemia; Prelamin A; Protein farnesyltransferase; Protein geranylgeranyltransferase

Indexed keywords

ACTIN; ALBUMIN; AMINOTRANSFERASE; CRE RECOMBINASE; DIMETHYLALLYLTRANSFERASE; PROTEIN CAAX PRENYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN GERANYLGERANYLTRANSFERASE I; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT DILATATION; CELL SHAPE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME SPECIFICITY; HEPATOSPLENOMEGALY; HYPERBILIRUBINEMIA; KNOCKOUT MOUSE; LIVER DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS FIBER; TRANSGENE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; DIMETHYLALLYLTRANSTRANSFERASE; FARNESYLTRANSTRANSFERASE; HEPATOCYTES; LIVER; LIVER DISEASES; MICE; MICE, KNOCKOUT; PROTEIN PRENYLATION;

EID: 84455172921     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M021220     Document Type: Article

References (42)

1. Casey, P. J., and M. C. Seabra. 1996. Protein prenyltransferases. J. Biol. Chem. 271: 5289-5292. (Pubitemid 26083855)
2. Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65: 241-269. (Pubitemid 26250610)
3. Casey, P. J., P. A. Solski, C. J. Der, and J. E. Buss. 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA. 86: 8323-8327. (Pubitemid 19286052)
4. Hancock, J. F., A. I. Magee, J. E. Childs, and C. J. Marshall. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 57: 1167-1177. (Pubitemid 19169813)
5. Cox, A. D., M. M. Hisaka, J. E. Buss, and C. J. Der. 1992. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol. Cell. Biol. 12: 2606-2615.
6. Lerner, E. C., A. D. Hamilton, and S. M. Sebti. 1997. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Anticancer Drug Des. 12: 229-238. (Pubitemid 27234747)
7. Gibbs, J. B., A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77: 175-178. (Pubitemid 24138615)
8. Tamanoi, F. 1993. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci. 18: 349-353. (Pubitemid 23258293)
9. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C. Marsters, Jr. 1993. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260: 1937-1942. (Pubitemid 23258274)
10. Sebti, S. M., and A. D. Hamilton. 2000. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-6593. (Pubitemid 32197696)
11. Lobell, R. B., C. A. Omer, M. T. Abrams, H. G. Bhimnathwala, M. J. Brucker, C. A. Buser, J. P. Davide, S. J. deSolms, C. J. Dinsmore, M. S. Ellis-Hutchings, et al. 2001. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61: 8758-8768. (Pubitemid 34013888)
12. Mijimolle, N., J. Velasco, P. Dubus, C. Guerra, C. A. Weinbaum, P. J. Casey, V. Campuzano, and M. Barbacid. 2005. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell. 7: 313-324. (Pubitemid 40544649)
13. He, B., P. Chen, S-Y. Chen, K. L. Vancura, S. Michaelis, and S. Powers. 1991. RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc. Natl. Acad. Sci. USA. 88: 11373-11377. (Pubitemid 21916043)
14. Vallim, M. A., L. Fernandes, and J. Alspaugh. 2004. The RAM1 gene encoding a protein-farnesyltransferase β-subunit homologue is essential in Cryptococcus neoformans. Microbiology. 150: 1925-1935. (Pubitemid 38923690)
15. Hanrahan, E. O., M. Kies, B. Glisson, F. Khuri, L. Feng, H. Tran, L. Ginsberg, M. Truong, W. Hong, and E. Kim. 2009. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am. J. Clin. Oncol. 32: 274-279.
16. Santucci, R., P. Mackley, S. Sebti, and M. Alsina. 2003. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control. 10: 384-387. (Pubitemid 37296065)
17. Lee, R., S. Y. Chang, H. Trinh, Y. Tu, A. C. White, B. S. Davies, M. O. Bergo, L. G. Fong, W. E. Lowry, and S. G. Young. 2010. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum. Mol. Genet. 19: 1603-1617.
18. Kazi, A., A. Carie, M. Blaskovich, C. Bucher, V. Thai, S. Moulder, H. Peng, D. Carrico, E. Pusateri, W. Pledger, et al. 2009. Blockade of protein geranylgeranylation inhibits cdk2-dependent p27Kip1 phosphorylation on thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol. Cell. Biol. 29: 2254-2263.
19. Lu, J., L. Chan, H. Fiji, R. Dahl, O. Kwon, and F. Tamanoi. 2009. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase I. Mol. Cancer Ther. 8: 1218-1226.
20. Sjogren, A. K., K. M. Andersson, M. Liu, B. A. Cutts, C. Karlsson, A. M. Wahlstrom, M. Dalin, C. Weinbaum, P. J. Casey, A. Tarkowski, et al. 2007. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J. Clin. Invest. 117: 1294-1304. (Pubitemid 46718417)
21. Liu, M., A. Sjogren, C. Karlsson, M. Lbrahim, K. Andersson, F. Olofsson, A. Wahistrom, M. Dalin, H. Yu, Z. Chen, et al. 2010. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc. Natl. Acad. Sci. USA. 107: 6471-6476.
22. Khan, O. M., M. X. Ibrahim, I. Jonsson, C. Karlsson, M. Liu, A. Sjogren, F. Olofsson, M. Brisslert, S. Andersson, C. Ohlsson, et al. 2011. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J. Clin. Invest. 121: 628-639.
23. Weisend, C. M., J. Kundert, E. Suvorova, J. Prigge, and E. Schmidt. 2009. Cre activity in fetal albCre mouse hepatocytes: utility for developmental studies. Genesis. 47: 789-792.
24. Anzo, M., L. Cobb, D. Hwang, H. Mehta, J. Said, S. Yakar, D. LeRoith, and P. Cohen. 2008. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res. 68: 3342-3349.
25. Seglen, P. O. 1976. Preparation of isolated rat liver cells. Methods Cell Biol. 13: 29-83.
26. Klaunig, J. E., P. Goldblatt, D. Hinton, M. Lipsky, J. Chacko, and B. Trump. 1981. Mouse liver cell culture. I. Hepatocyte isolation. In Vitro. 17: 913-925. (Pubitemid 12181443)
27. Livak, K. J., and T. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25: 402-408. (Pubitemid 34164012)
28. Fong, L. G., J. K. Ng, M. Meta, N. Cote, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al. 2004. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. USA. 101: 18111-18116. (Pubitemid 40054082)
29. Fong, L. G., J. K. Ng, J. Lammerding, T. A. Vickers, M. Meta, N. Cote, B. Gavino, X. Qiao, S. Y. Chang, S. R. Young, et al. 2006. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J. Clin. Invest. 116: 743-752. (Pubitemid 43326883)
30. Toth, J. I., S. H. Yang, X. Qiao, A. P. Beigneux, M. H. Gelb, C. L. Moulson, J. H. Miner, S. G. Young, and L. G. Fong. 2005. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. USA. 102: 12873-12878. (Pubitemid 41279458)
31. Yang, S. H., M. O. Bergo, J. I. Toth, X. Qiao, Y. Hu, S. Sandoval, M. Meta, P. Bendale, M. H. Gelb, S. G. Young, et al. 2005. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. USA. 102: 10291-10296. (Pubitemid 41023365)
32. Yang, S. H., D. Andres, H. Spielmann, S. Young, and L. Fong. 2008. Progerin elicits disease whether or not it is farnesylated. J. Clin. Invest. 118: 3291-3300.
33. Steinert, P., R. Zackroff, M. Aynardi-Whitman, and R. D. Goldman. 1982. Isolation and characterization of intermediate filaments. Methods Cell Biol. 24: 399-419. (Pubitemid 12055910)
34. Folch, J., M. Lees, and G. H. S. Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
35. Hall, A. 1998. Rho GTPases and the actin cytoskeleton. Science. 279: 509-514. (Pubitemid 28067271)
36. Powers, S., S. Michaelis, D. Broek, S. S. Anna-A., J. Field, I. Herskowitz, and M. Wigler. 1986. RAM, a gene of yeast required for a functional modification of RAS proteins and for production of mating pheromone a-factor. Cell. 47: 413-422. (Pubitemid 17210155)
37. Yang, S. H., M. O. Bergo, E. Farber, X. Qiao, L. G. Fong, and S. G. Young. 2009. Caution! Analyze transcripts from conditional knockout alleles. Transgenic Res. 18: 483-489.
38. Sinensky, M., L. A. Beck, S. Leonard, and R. Evans. 1990. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J. Biol. Chem. 265: 19937-19941. (Pubitemid 120013953)
39. Yang, S. H., M. Meta, X. Qiao, D. Frost, J. Bauch, C. Coffinier, S. Majumdar, M. O. Bergo, S. G. Young, and L. G. Fong. 2006. Treatment with a protein farnesyltransferase inhibitor improves disease phenotypes in mice with a targeted Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest. 116: 2115-2121. (Pubitemid 44162320)
40. Fong, L. G., D. Frost, M. Meta, X. Qiao, S. Yang, C. Coffinier, and S. Young. 2006. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 311: 1621-1623.
41. Young, S. G., M. Meta, S. H. Yang, and L. G. Fong. 2006. Prelamin A farnesylation and progeroid syndromes. J. Biol. Chem. 281: 39741-39745. (Pubitemid 46041777)
42. Varela, I., S. Pereira, A. P. Ugalde, C. L. Navarro, M. F. Suarez, P. Cau, J. Cadinanos, F. G. Osorio, N. Foray, J. Cobo, et al. 2008. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14: 767-772.